[Buruli ulcer in Angolese refugees in the Kimpese area, Lower Congo, D.R. Congo].

Many epidemiological studies on Buruli ulcer have established the endemic zones in the Congolese Democratic Republic. But the situation about the areas where the refugees are located in high endemicity zones has not yet been studied. The present study describes the presence of the Mycobacterium ulcerans infection in the angolese refugee populationat Kimpese.

Antimalarial activity of 20 crude extracts from nine African medicinal plants used in Kinshasa, Congo.

Twenty extracts including ten EtOH and ten CH2Cl2 from different parts of nine African medicinal plants used in Congolese traditional medicine for the treatment of malaria, were submitted to a pharmacological test in order to evaluate their effect on P. falciparum growth in vitro. Of these plant species, 14 (70%) extracts including EtOH and CH2Cl2 from Cassia occidentalis leaves, Cryptolepis sanguinolenta root bark, Euphorbia hirta whole plant, Garcinia kola stem bark and seeds, Morinda lucida leaves and Phyllanthus niruri whole plant produced more than 60% inhibition of the parasite growth in vitro at a test concentration of 6 microg/ml.

[In vitro study of the adsorption of chloroquine by an antidiarrheal remedy traditionally used in Africa].

Mouboumou is a traditional medicine prepared from the inner part of termitarium and is used in traditional medicine in Zaire. In tropical diseases, antimalarial drugs are often used simultaneously with antidiarrheal absorbent drugs, which might, by their adsorbent properties, compromise the efficacy of the antimalarial treatment. The present in vitro study has allowed to determine the adsorption characteristics of chloroquine on Mouboumou; kaopectate was used a reference adsorbent.

[New antimalarial sustained-release formulations based on bioresorbable polymers: therapeutic evaluation using the Plasmodium berghei model].

Chemotherapy keeps an important place in malaria control programme. The development of schizonticidal formulations, which may maintain their efficacy for at least one month after single administration, becomes needful. These formulations should allow to assure a suitable patient compliance and to avoid the disadvantages of high plasmatic peaks.